Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Launched by BEIJING CHAO YANG HOSPITAL · Apr 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the risks of blood clots in lung cancer patients who are receiving a type of treatment called immune checkpoint inhibitors (ICIs). Blood clots can occur in the veins (venous thromboembolism, or VTE) or arteries (arterial thromboembolism, or ATE), and the researchers want to understand how common these clots are in patients taking ICIs, what factors may increase the risk of developing them, and how these clots might affect a patient's overall health and treatment outcomes. By comparing patients who experience blood clots with those who do not, the researchers hope to find specific markers that could help predict who might be at higher risk for these complications.

To participate in the trial, individuals must be at least 18 years old, have a confirmed diagnosis of lung cancer, and have received at least one dose of a lung cancer ICI approved for use in China. Participants will be asked to sign a consent form, and those who meet the criteria will contribute to valuable research that could improve how doctors identify and manage blood clot risks in lung cancer patients. The study is currently recruiting participants, and everyone involved will help advance our understanding of how to better prevent and treat blood clots in this patient population.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Histopathologically confirmed lung cancer diagnosis at enrollment
• • Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor
• • Signed informed consent form
• Exclusion Criteria:
• • Excluded based on inclusion criteria
• • Cannot comply with follow-up requirements